News

  • All
  • Nirogy News
  • Press Releases
All
  • All
  • Nirogy News
  • Press Releases
Press Releases

Nirogy Therapeutics to Present at AACR Annual Meeting 2021

E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous killing of cancer cells …

Read More →
Nirogy News

Market ‘Solutes’ Nirogy Small-Molecule Flag with $16.5M Series A

Boston-based Nirogy Therapeutics Inc.’s $16.5 million series A round is meant to enable a pipeline of small-molecule drugs targeting the solute carrier family of transporter …

Read More →
Nirogy News

Nirogy Therapeutics Emerges with $16.5M to Target Metabolite Transporters

Over the next year, Nirogy will narrow its lactate transporter inhibitor candidates down to one for preclinical development and IND-enabling studies. (Getty/EPlus/asonfang) After years working …

Read More →
Nirogy News

Nirogy Raises $16.5 Million to Focus on Transporter Proteins

Nirogy Therapeutics, based in Boston, launched with a $16.5 million Series A financing round. The round was co-led by Santé Ventures and Sporos. Nirogy is …

Read More →
Press Releases

Nirogy Therapeutics Launches with $16.5 Million Series A Financing

Proceeds to support the development of small-molecule drugs that modulate the transport of metabolites for oncology and immunology indications Boston, January 26, 2021 – Nirogy …

Read More →
Press Releases

Nirogy Therapeutics is Awarded $2 Million NIH/NCI SBIR Grant to Develop dMCTi for TNBC

Nirogy Therapeutics Inc. today announced that it was awarded a $2M NIH/NCI SBIR grant to develop dual monocarboxylate transport inhibitors (dMCTi) for Triple Negative Breast …

Read More →
Scroll to Top

This website uses cookies to ensure you get the best experience on our website.

Vincent P. Sandanayaka, Ph.D.

FOUNDER

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat